Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
Launched by PFIZER · Apr 2, 2019
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of Atopic Dermatitis for at least 3 months
- • Investigator's Global Assessment (IGA) Score of 2 or 3
- • Eczema Area Severity Index (EASI) score of 3-21
- • Body Surface Area (BSA) of 2-20%
- • Peak pruritus-Numerical Rating Scale (PPNRS) of Grade 2 or more
- Exclusion Criteria:
- • Other forms of dermatological diseases (other than atopic dermatitis)
- • Fitzpatrick skin type score greater than 5
- • Clinically significant abnormal ECG, vital signs, and laboratory values
- • Infection with HBV, HCV, herpes zoster or tuberculosis
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jacksonville, Florida, United States
Oklahoma City, Oklahoma, United States
Malvern, Victoria, Australia
Frankfurt, , Germany
Normal, Illinois, United States
Memphis, Tennessee, United States
Berlin, , Germany
Hellerup, , Denmark
Rapid City, South Dakota, United States
Winnipeg, Manitoba, Canada
Santa Monica, California, United States
Schwerin, , Germany
Tulsa, Oklahoma, United States
Maroubra, New South Wales, Australia
Jacksonville, Florida, United States
Orlando, Florida, United States
Debrecen, , Hungary
Szeged, , Hungary
Saint Joseph, Missouri, United States
Camberwell, Victoria, Australia
East Melbourne, Victoria, Australia
Miskolc, , Hungary
Encinitas, California, United States
Torun, , Poland
Bonn, , Germany
Clearwater, Florida, United States
Ormond Beach, Florida, United States
Shelton, Connecticut, United States
Louisville, Kentucky, United States
Kecskemet, , Hungary
Berlin, , Germany
Berlin, , Germany
High Point, North Carolina, United States
Hamburg, , Germany
Deland, Florida, United States
Fountain Valley, California, United States
New Albany, Indiana, United States
Birmingham, Alabama, United States
Long Beach, California, United States
Baton Rouge, Louisiana, United States
Memphis, Tennessee, United States
Franklin, Virginia, United States
Norfolk, Virginia, United States
Montreal, Quebec, Canada
Mahlow, , Germany
Riga, , Latvia
Riga, , Latvia
Ventspils, , Latvia
Webster, Texas, United States
Sherbrooke, Quebec, Canada
Jacksonville, Florida, United States
Sofia, , Bulgaria
Sandy Springs, Georgia, United States
Scottsdale, Arizona, United States
Scottsdale, Arizona, United States
Cypress, Texas, United States
Sofia, , Bulgaria
Sofia, , Bulgaria
Cobourg, Ontario, Canada
Bielefeld, , Germany
Hamburg, , Germany
Budapest, , Hungary
Sapporo Shi, Hokkaido, Japan
Kita Ku, Osaka Shi, Osaka, Japan
Minato Ku, Tokyo, Japan
Ota Ku, Tokyo, Japan
Tachikawa, Tokyo, Japan
Warszawa, , Poland
Wroclaw, , Poland
Bridgeport, Connecticut, United States
Washington, District Of Columbia, United States
Jacksonville, Florida, United States
Houston, Texas, United States
Hurst, Texas, United States
Shinjuku Ku, Tokyo, Japan
Bialystok, , Poland
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials